Regeneron Pharmaceuticals D
D
REGN
542.46
USD
-7.51
(-1.37%)
مغلق
حجم التداول
55,771
الربح لكل سهم
36
العائد الربحي
0.32
P/E
14
حجم السوق
58,566,963,503
الأخبار المقالات
العنوان: Regeneron Pharmaceuticals
القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).